Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. (Nasdaq: PCVX) is a clinical-stage vaccine innovation company focused on broad-spectrum bacterial vaccines, and its news flow reflects progress across multiple pneumococcal conjugate vaccine programs and related manufacturing and regulatory milestones. Company announcements frequently highlight clinical trial updates for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult program and being evaluated in a Phase 2 infant study, as well as VAX-24, a 24-valent PCV candidate in a Phase 2 infant study.
Investors and observers following PCVX news can expect detailed coverage of Phase 2 and Phase 3 study designs, topline safety, tolerability and immunogenicity data, and dose-selection decisions for both adult and pediatric indications. Recent releases have described the OPUS adult Phase 3 pivotal noninferiority trial for VAX-31, the multi-stage VAX-31 infant dose-finding study, and positive topline results from the VAX-24 infant Phase 2 trial, including IgG and opsonophagocytic assay responses compared with existing PCVs.
Vaxcyte’s news also covers regulatory interactions and designations, such as the U.S. Food and Drug Administration’s Breakthrough Therapy designation for VAX-31 in adults and its expansion to include prevention of pneumonia caused by Streptococcus pneumoniae. In addition, the company reports on manufacturing and supply-chain developments, including a dedicated manufacturing suite at Lonza and a long-term agreement with Thermo Fisher Scientific’s Patheon unit to provide fill-finish capacity in Greenville, North Carolina as part of its U.S. commercial supply strategy.
Other updates include business and financial results, capital allocation priorities, early-stage pipeline decisions involving candidates such as VAX-A1 and VAX-GI, and governance changes such as board and executive appointments. For readers tracking PCVX, this news page offers an ongoing view into Vaxcyte’s clinical progress, regulatory pathway, manufacturing readiness and corporate developments around its pneumococcal and broader bacterial vaccine pipeline.
Vaxcyte, Inc. has announced the promotion of Andrew Guggenhime to President and Chief Financial Officer, effective January 1, 2021. This transition reflects the company's leadership evolution as it aims to scale operations and advance its vaccine pipeline, especially the pneumococcal vaccine candidate VAX-24. Guggenhime, who joined Vaxcyte in May 2020, brings over two decades of financial and operational experience in the healthcare sector.
Vaxcyte focuses on developing innovative vaccines to combat infectious diseases globally, leveraging its cell-free protein synthesis platform for vaccine creation.
Vaxcyte, formerly SutroVax, announced participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on December 2, 2020, at 1:50 PM ET. The event aims to discuss the company’s innovative vaccine developments targeting widespread infectious diseases. A live webcast will be available on the company’s website, with a replay offered for 30 days post-event. Vaxcyte is advancing several candidates, including VAX-24, a preclinical 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease.
Vaxcyte announced its Q3 2020 financial results, highlighting a net loss of $21 million compared to $11.3 million in Q3 2019. The company’s cash position improved significantly to $397 million, up from $59 million at the end of 2019, following its IPO and Series D financing. Vaxcyte reported R&D expenses of $16.4 million, primarily due to increased manufacturing costs for its VAX-24 program, and G&A expenses rose to $4.9 million. Key milestones include an anticipated IND filing for VAX-24 in the second half of 2021 and ongoing progression in its vaccine pipeline.
Vaxcyte, a next-generation vaccine company, announced its participation at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:35 PM ET. The presentation aims to showcase Vaxcyte's innovative vaccine development efforts for preventing common infectious diseases. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-event. Vaxcyte's pipeline includes vaccines for pneumococcal disease, Group A Strep infections, and periodontal disease, leveraging a unique cell-free protein synthesis platform.
Vaxcyte, formerly known as SutroVax, announced participation in the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, at 11:00 a.m. ET. The company aims to enhance global health through innovative vaccines targeting infectious diseases. Their lead candidate, VAX-24, is a preclinical 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease. Vaxcyte's platform, XpressCF™, enables advanced vaccine development, including candidates for Group A Strep infections and periodontal disease. Access the live webcast and replay via their website.
Summary not available.
Vaxcyte, Inc. reported its Q2 2020 financial results and highlighted significant advancements in its vaccine development pipeline. The company completed a successful IPO, raising $264.1 million, and achieved crucial manufacturing milestones for its lead candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine. R&D expenses rose to $18.2 million due to increased manufacturing efforts. However, the net loss increased to $20.3 million, up from $10.7 million year-over-year. The company aims to submit an IND application for VAX-24 in H2 2021.
Vaxcyte, a next-generation vaccine company, has successfully closed its initial public offering, issuing 17,968,750 shares at $16.00 each, including the full underwriter's option of 2,343,750 shares. This IPO raised $287.5 million in gross proceeds, facilitating the company's mission to develop innovative vaccines for serious infectious diseases. The shares began trading on Nasdaq under the ticker symbol 'PCVX' on June 12, 2020. Vaxcyte utilizes a cutting-edge protein synthesis platform to enhance vaccine development, focusing on pneumococcal conjugate vaccines and other novel therapies.